natgillin/translations-raw huggingface dataset:
The most commonly reported adverse reactions associated with anagrelide were headache occurring at approximately 14%, palpitations occurring at approximately 9%, fluid retention and nausea both occurring at approximately 6% and diarrhoea occurring at 5%.
Najpogosteje zabeleženi neželeni učinki, povezani z anagrelidom, so bili glavobol, ki se je pojavil pri približno 14 % bolnikov, palpitacije so se pojavile pri približno 9 % bolnikov, zastajanje tekočine in slabost sta se pojavila pri približno 6 % bolnikov in driska pri 5 % bolnikov.
• At the doses recommended for use in the treatment of essential thrombocythaemia, anagrelide may potentiate the effects of other medicinal products that inhibit or modify platelet function e.g. acetylsalicylic acid.
• Pri priporočenih odmerkih pri zdravljenju esencialne trombocitemije utegne anagrelid okrepiti učinke drugih zdravil, ki zavirajo ali spreminjajo funkcijo trombocitov, npr. učinke acetilsalicilne kisline.
Each capsule contains approximately 59.5 mg lactose.
Ena kapsula vsebuje približno 59,5 mg laktoze.
If needed, anagrelide dose adjustment could be made.
Po potrebi bi lahko prilagodili odmerek anagrelida.
Anagrelide is primarily metabolised by CYP1A2 to form, 3-hydroxy anagrelide, which is further metabolised via CYP1A2 to the inactive metabolite, 2-amino-5, 6-dichloro-3, 4-dihydroquinazoline.
Anagrelid se v glavnem presnavlja s CYP1A2, da nastane 3-hidroksi anagrelid, ki ga CYP1A2 še nadalje presnovi v neaktivni presnovek 2-amino-5, 6-dikloro-3, 4-dihidrokinazolin.
The recommended starting dose of anagrelide is 1 mg/day, which should be administered orally in two divided doses (0.5 mg/dose).
Priporočen začetni odmerek anagrelida je 1 mg dnevno, jemati ga je treba peroralno v dveh ločenih odmerkih (0,5 mg na odmerek).
SPECIAL STORAGE CONDITIONS Store in the original package in order to protect from light and moisture.
POSEBNA NAVODILA ZA SHRANJEVANJE Shranjujte v originalni ovojnini za zagotovitev zaščite pred svetlobo in vlago.
In an open-label clinical study in 8 children and 10 adolescents (including patients who were anagrelide treatment naïve or who had been receiving anagrelide for up to 5 years pre-study), median platelet counts were decreased to controlled levels after 12 weeks of treatment.
V odprti klinični študiji pri 8 otrocih in 10 mladostnikih (vključno z bolniki, ki prej niso prejemali anagrelida ali ki so pred študijo prejemali anagrelid do 5 let dolgo) se je mediana koncentracija trombocitov po 12 tednih zdravljenja zmanjšala na kontrolirane vrednosti.
Evidence of similar in vivo actions was observed in bone marrow biopsy samples from treated patients.
Dokaze podobnega delovanja in vivo so opazili pri biopsiji vzorcev kostnega mozga, ki so jih odvzeli zdravljenim bolnikom.
Pharmacokinetic data from fasting elderly patients with ET (age range 65 - 75 years) compared to fasting adult patients (age range 22 - 50 years) indicate that the Cmax and AUC of anagrelide were 36% and 61% higher respectively in elderly patients, but that the Cmax and AUC of the active metabolite, 3hydroxy anagrelide, were 42% and 37% lower respectively in the elderly patients.
Farmakokinetični podatki, pridobljeni od starejših teščih bolnikov z ET (starostni okvir 65-75 let) v primerjavi s teščimi odraslimi bolniki (starostni okvir 22-50 let), kažejo, da so bile vrednosti Cmax anagrelida za 36 % in vrednosti AUC anagrelida 61 % višje pri starejših bolnikih, medtem ko so bile vrednosti Cmax aktivnega presnovka 3-hidroksi -anagrelida pri starejših bolnikih za 42 % nižje, vrednosti AUC pa za 37 % nižje.
Use of concomitant anagrelide and acetylsalicylic acid has been associated with major haemorrhagic events (see section 4.5).
Sočasna uporaba anagrelida in acetilsalicilne kisline je bila povezana z večjimi hemoragičnimi dogodki (glejte poglavje 4.5).
Blood creatinine increased
Preiskave povečan kreatinin v krvi
Treatment with anagrelide should be initiated by a clinician with experience in the management of essential thrombocythaemia.
Zdravljenje z anagrelidom mora vpeljati zdravnik, ki ima izkušnje z zdravljenjem esencialne trombocitemije.
Serious cardiovascular adverse reactions including cases of torsade de pointes, ventricular tachycardia, cardiomyopathy, cardiomegaly and congestive heart failure have been reported (see section 4.8).
Poročali so o resnih kardiovaskularnih neželenih učinkih, vključno s primeri torsade de pointes, ventrikularne tahikardije, kardiomiopatije, kardiomegalije in kongestivnega popuščanja srca (glejte poglavje 4.8).
If you notice any of these side effects, contact your doctor immediately.
Če opazite katerega od teh neželenih učinkov, se nemudoma obrnite na svojega zdravnika.
• Omeprazole, used to reduce the amount of acid produced in the stomach;
• omeprazol, ki se uporablja za zmanjšanje nastajanja želodčne kisline;
These adverse drug reactions are expected based on the pharmacology of anagrelide (inhibition of PDE III).
Ti neželeni učinki zdravila temeljijo na farmakologiji anagrelida (zaviranju PDE III).
Post-marketing case reports of intentional overdose with anagrelide have been received.
Po začetku trženja zdravila so bili zabeleženi primeri namernega prevelikega odmerjanja anagrelida.
In this study 34 patients received anagrelide for up to 5 years.
V tej študiji je 34 bolnikov anagrelid prejemalo do 5 let.
If anagrelide is used during pregnancy, or if the patient becomes pregnant while using the medicinal product, she should be advised of the potential risk to the foetus.
V primeru uporabe anagrelida med nosečnostjo ali če bolnica v času uporabe zdravila zanosi, moramo nosečnico seznaniti z morebitnim tveganjem za zarodek.
Very common
Zelo pogosti Pogosti
Therefore, clinical and biological monitoring is recommended in patients taking concomitant CYP1A2 inducers.
Zato je pri bolnikih, ki sočasno jemljejo spodbujevalce CYP1A2, priporočljivo klinično in biološko spremljanje.
A transient increase in mean QTc was observed for both doses during periods of increasing heart rate and the maximum change in mean QTcF (Fridericia correction) was +5.0 msec occurring at 2 hours for 0.5 mg and +10.0 msec occurring at 1 hour for 2.5 mg.
Opazili so prehodno podaljšanje povprečnega intervala QTc za oba odmerka v času pospeševanja srčnega utripa in največja sprememba povprečnega QTcF (popravek Fridericia) je bila +5,0 milisekund po 2 urah pri odmerku 0,5 mg in +10,0 milisekund po 1 uri pri odmerku 2,5 mg.
No human data on the effect of anagrelide on fertility are available.
Podatkov o učinku anagrelida na plodnost pri ljudeh ni na voljo.
What Anagrelide Mylan is and what it is used for
Kaj je zdravilo Anagrelid Mylan in za kaj ga uporabljamo
An allergic reaction may be recognised as a rash, itching, swollen face or lips, or shortness of breath;
Alergična reakcija se utegne pokazati v obliki izpuščaja, srbečice, oteklega obraza ali ustnic ali zasoplosti;
Anagrelide is indicated for the reduction of elevated platelet counts in at risk essential thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy.
Anagrelid je indiciran za zmanjšanje povečanega števila trombocitov pri bolnikih, ki so izpostavljeni tveganju za pojav esencialne trombocitemije (ET) in ki se ne odzivajo na trenutno zdravljenje, ali pri bolnikih, katerih povišano število trombocitov se s trenutnim načinom zdravljenja ni zmanjšalo na sprejemljivo raven.
Your doctor may do a blood test which may show an increase in your liver enzymes.
Zdravnik lahko odredi tudi odvzem krvi in tako ugotovi morebitno zvišanje jetrnih encimov.
In these studies 22 patients received anagrelide for up to 4 years.
V teh študijah je 22 bolnikov anagrelid prejemalo do 4 leta.
The amount of anagrelide that people take can be different, and this depends on your condition.
Odmerki anagrelida, ki jih prejemajo bolniki, so lahko različni, saj so odvisni od stopnje bolezni.
If you are not sure, speak to your doctor or pharmacist for advice.
Če niste prepričani, za nasvet povprašajte zdravnika ali farmacevta.
• In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the pharmacokinetic properties of anagrelide.
• Študije medsebojnega delovanja pri ljudeh in vivo so pokazale, da digoksin in varfarin ne vplivata na farmakokinetične lastnosti anagrelida.
• Anagrelide demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other co-administered medicinal products sharing that clearance mechanism e.g. theophylline.
• Anagrelid kaže nekatere zaviralne lastnosti do CYP1A2, kar utegne teoretično predstavljati možnost za medsebojno delovanje z drugimi zdravili, ki so uporabljeni istočasno in ki si delijo ta mehanizem očistka, npr. teofilin.
Anagrelide, at higher than recommended doses, has been shown to produce reductions in blood pressure with occasional instances of hypotension.
Anagrelid je pri višjih odmerkih od priporočenih povzročil padec krvnega tlaka z občasnimi primeri hipotenzije.
UNIQUE IDENTIFIER - 2D BARCODE Carton only:
EDINSTVENA OZNAKA - DVODIMENZIONALNA ČRTNA KODA Samo na škatli:
• Inflammation of the liver, symptoms include nausea, vomiting, itching, yellowing of the skin and eyes, discoloration of stool and urine (hepatitis);
• vnetje jeter, simptomi vključujejo slabost, bruhanje, srbenje, rumeno obarvanje kože in oči,razbarvanje blata in urina (hepatitis);
Therapy requires close clinical supervision of the patient which will include a full blood count (haemoglobin and white blood cell and platelet counts), assessment of liver function (ALT and AST), renal function (serum creatinine and urea) and electrolytes (potassium, magnesium and calcium).
Zdravljenje zahteva natančno klinično spremljanje bolnika, kar vključuje tudi popolno analizo krvi (ugotavljanje količine hemoglobina, števila belih krvničk in trombocitov), oceno delovanja jeter (ALT in AST), oceno delovanja ledvic (serumski kreatinin in sečnina) in vrednosti elektrolitov (kalij, magnezij in kalcij).
The maximum change in mean heart rate occurred at 2 hours after administration and was +7.8 beats per minute (bpm) for 0.5 mg and +29.1 bpm for 2.5 mg.
Do največje spremembe povprečnega srčnega utripa je prišlo 2 uri po odmerjanju in sicer +7,8 utripov na minuto pri odmerku 0,5 mg in +29,1 utripov na minuto pri odmerku 2,5 mg.
In fasted subjects, peak plasma levels occur about 1 hour after administration.
Pri osebah, ki so bile tešče, se najvišja plazemska koncentacija doseže približno 1 uro po jemanju.
• a platelet count > 1,000 x 109/l or
• število trombocitov, ki je višje od 1.000 × 109/l, ali
In the later study 3,660 patients who received anagrelide at a mean dose of approximately 2 mg/day were assessed for safety.
V zadnji študiji so glede varnosti ocenjevali 3.660 bolnikov, ki so prejemali povprečni odmerek anagrelida približno 2 mg dnevno.
Embryofoetal development studies
Študije razvoja zarodkov in plodov
• Oral contraceptives: If you experience bad diarrhoea whilst taking this medicine, it may reduce how well the oral contraceptive works and use of an extra method of contraception is recommended (e.g. condom).
Če dobite pri jemanju tega zdravila močno drisko, se lahko zmanjša učinkovitost delovanja peroralne kontracepcije, zato je priporočljiva uporaba dodatne kontracepcijske metode (npr. kondoma).
They were observed in females receiving 30 mg/kg/day, corresponding to 572 times the human AUC exposure after a 1 mg twice daily dose.
Opazili so jih pri samicah, ki so prejemale 30 mg/kg/dan, kar je enako 572-kratniku AUC pri ljudeh pri odmerjenju 1 mg dvakrat dnevno.
What you need to know before you take Anagrelide Mylan
Kaj morate vedeti, preden boste vzeli zdravilo Anagrelid Mylan
LIST OF EXCIPIENTS Contains lactose and sodium.
SEZNAM POMOŽNIH SNOVI Vsebuje laktozo in natrij.
• In vivo interaction studies in humans have demonstrated that anagrelide does not affect the pharmacokinetic properties of digoxin or warfarin.
• In vivo študije medsebojnega delovanja pri ljudeh so pokazale, da anagrelid ne vpliva na farmakokinetične lastnosti digoksina in varfarina.
In earlier, open-label studies, median platelet count reductions were observed in 7 children and 9 adolescents treated for between 3 months and 6.5 years.
V prejšnjih odprtih študijah so pri 7 otrocih in 9 adolescentih, ki so se zdravili med 3 mesece in 6,5 let dolgo, opazili zmanjšanje mediane koncentracije trombocitov.
Among them, the incidence of adrenal phaeochromocytomas was increased relative to control in males at all dose levels (≥ 3 mg/kg/day) and in females receiving 10 mg/kg/day and above.
Pojav nadledvičnega feokromocitoma je bil pogostejši v primerjavi s kontrolno skupino pri samcih pri vseh odmerkih (≥ 3 mg/kg/dan) in pri samicah, ki so prejemale 10 mg/kg/dan in več.
The disease may progress to myelofibrosis or AML.
Bolezen lahko napreduje v mielofibrozo ali akutno mieloblastno levkemijo (AML).
Pack size: 100 hard capsules.
Velikosti pakiranja: 100 trdih kapsul.
Concomitant use of anagrelide with other PDE III inhibitors such as milrinone, amrinone, enoximone, olprinone and cilostazol is not recommended.
Sočasna uporaba anagrelida z drugimi zaviralci PDE III, kot so milrinon, amrinon, enoksimon, olprinon in cilostazol, ni priporočljiva.
• Other medicines used to treat conditions affecting the platelets in your blood, e.g. clopidogrel;
• druga zdravila, ki se uporabljajo za zdravljenje bolezni, ki vplivajo na trombocite, npr. klopidogrel;
Therefore, it is recommended that patients with moderate or severe hepatic impairment are not treated with anagrelide.
Priporočljivo je, da bolnikov z zmerno ali zelo oslabljenimi jetri ne zdravimo z anagrelidom.
Patients with moderate or severe hepatic impairment.
Bolnik z zmerno ali močno oslabljenim delovanjem jeter.
If your doctor stops your medicine, do not keep any leftover capsules unless your doctor tells you to. Do not throw away any medicines via wastewater or household waste.
Če zdravnik prekine zdravljenje z zdravilom, ne hranite neporabljenih kapsul, razen če vam tega ne naroči zdravnik.
Anagrelide is an inhibitor of cyclic AMP phosphodiesterase III (PDE III).
Anagrelid je zaviralec ciklične AMP fosfodiesteraze III (PDE III).
• Lung inflammation (signs include fever, coughing, difficulty breathing, wheezing; which causes scaring of the lungs) (allergic alveolitis, including interstitial lung disease, pneumonitis);
• vnetje pljuč (znaki vključujejo povišano telesno temperaturo, kašelj, oteženo dihanje,sopenje; ki povzroči brazgotinjenje pljuč) (alergijski alveolitis (vnetje pljučnih alveolov), vključno z intersticijsko boleznijo pljuč, pljučnica);
The usual starting dose of this medicine is 1 mg. You take this dose as one capsule of 0.5 mg twice a day, for at least a week.
Ta odmerek jemljete tako, da jemljete eno kapsulo po 0,5 mg dvakrat na dan vsaj en teden.
The precise mechanism by which anagrelide reduces blood platelet count is unknown.
Natančni mehanizem, s katerim anagrelid zmanjša število trombocitov v krvi, ni znan.
In combination with acetylsalicylic acid (a substance present in many medicines used to relieve pain and lower fever, as well as to prevent blood clotting, also known as aspirin), there is an increased risk of major haemorrhages (bleeding) (see section “Other medicines and Anagrelide Mylan”).
V kombinaciji z acetilsalicilno kislino (učinkovina, ki je prisotna v številnih zdravilih, ki se uporabljajo za lajšanje bolečin in zniževanje zvišane telesne temperature, pa tudi za preprečevanje strjevanja krvi) obstaja povečano tveganje za velike krvavitve (hemoragijo) (glejte poglavje „Druga zdravila in zdravilo Anagrelid Mylan“).
In some ET patients concomitantly treated by acetylsalicylic acid and anagrelide, major haemorrhages occurred.
Pri nekaterih bolnikih z ET, ki so se sočasno zdravili z acetilsalicilno kislino in anagrelidom, je prišlo do velikih krvavitev.
In 3 of the studies 942 patients who received anagrelide at a mean dose of approximately 2 mg/day were assessed for safety.
V treh študijah so glede varnosti ocenjevali 942 bolnikov, ki so prejemali povprečni odmerek anagrelida približno 2 mg dnevno.
CYP1A2 inducers
Zaviralci CYP1A2
In female rats, using doses in excess of the therapeutic range, anagrelide disrupted implantation (see section 5.3).
Pri samicah podgan je anagrelid pri uporabi odmerkov, ki so presegali terapevtsko območje, oviral ugnezditev (glejte poglavje 5.3).
Anagrelide is an inhibitor of cyclic AMP phosphodiesterase III.
Anagrelid je zaviralec ciklične AMP fosfodiesteraze III.
Do not crush the capsules or dilute the contents in a liquid.
Ne smete jih zdrobiti ali raztopiti njihove vsebine v tekočini.
• Acetylsalicylic acid (a substance present in many medicines used to relieve pain and lower fever, as well as to prevent blood clotting, also known as aspirin);
• acetilsalicilna kislina (učinkovina, ki je prisotna v številnih zdravilih, ki se uporabljajo za blaženje bolečin in zniževanje zvišane telesne temperature, pa tudi za preprečevanje strjevanja krvi);
INFORMATION IN BRAILLE Carton only: anagrelide mylan 1 mg
PODATKI V BRAILLOVI PISAVI Samo na škatli: anagrelid mylan 1 mg
If you forget to take Anagrelide Mylan
Če ste pozabili vzeti zdravilo Anagrelid Mylan
Caution should be taken when using anagrelide in patients with known risk factors for prolongation of the QT interval, such as congenital long QT syndrome, a known history of acquired QTc prolongation,
Kadar uporabljamo anagrelid pri bolnikih z znanimi dejavniki tveganja za podaljšanje intervala QT, na primer s prirojenim sindromom dolgega intervala QT, z znano anamnezo pridobljenega podaljšanja intervala QTc, pri uporabi zdravil, ki lahko podaljšajo interval QTc, in pri hipokaliemiji, je potrebna previdnost.
• If you have any problems with your liver or kidneys.
• če imate težave z delovanjem jeter ali ledvic.
The lowest dose in males (3 mg/kg/day) corresponds to 37 times the human AUC exposure after a 1 mg twice daily dose.
Najmanjši odmerek pri samcih (3 mg/kg/dan) je enak 37-kratniku AUC pri ljudeh pri odmerjenju 1 mg dvakrat dnevno.
Cardiac disorders
Kardiovaskularni sistem
Tell your doctor if you are pregnant or are planning to become pregnant.
Povejte zdravniku, če dojite ali če nameravate začeti dojiti.
• If you have moderate or severe liver problems;
• če imate zmerne ali hude težave z delovanjem jeter;
A capsule size 4 (approximately 14.3 x 5.3 mm) with an opaque white body and cap.
Kapsula velikosti št. 4 (približno 14,3 x 5,3 mm)z neprozornim belim telesom in pokrovčkom.
Anagrelide Mylan should not be taken by pregnant women.
Zdravila Anagrelid Mylan nosečnice ne smejo jemati.
How to store Anagrelide Mylan Contents of the pack and other information
Shranjevanje zdravila Anagrelid Mylan Vsebina pakiranja in dodatne informacije
Marketing Authorisation Holder Mylan S.A.S
Imetnik dovoljenja za promet z zdravilom Mylan S.A.S
However, hepatic metabolism represents the major route of anagrelide clearance and liver function may therefore be expected to influence this process.
Vendar predstavlja jetrna presnova glavno pot, po kateri se razgrajuje anagrelid in tako morda delovanje jeter vpliva na presnovo anagrelida.
Anagrelide Mylan contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially ‘sodium-free'.
Zdravilo Anagrelid Mylan vsebuje natrij To zdravilo vsebuje manj kot 1 mmol natrija (23 mg) na kapsulo, kar v bistvu pomeni ‘brez natrija'.
The mean recovery of 2-amino-5, 6-dichloro-3, 4-dihydroquinazoline in urine is approximately 18-35% of the administered dose.
V urinu se izloči povprečno približno 18-35 % danega odmerka v obliki 2-amino-5,6-dikloro-3, 4-dihidrokinazolina.
The other ingredients are lactose (see section 2 ‘Anagrelide Mylan contains lactose'), croscarmellose sodium, povidone, microcrystalline cellulose, magnesium stearate, gelatin and titanium dioxide(E171).
Druge sestavine zdravila so laktoza (glejte poglavje 2 „Zdravilo Anagrelid Mylan vsebuje laktozo“), premreženi natrijev karmelozat, povidon, mikrokristalna celuloza, magnezijev stearat, želatina in titanov dioksid (E171).
The other ingredients are lactose (see section 2 ‘Anagrelide Mylan contains lactose'), croscarmellose sodium, povidone, microcrystalline cellulose, magnesium stearate, gelatin, titanium dioxide (E171) and iron oxide black (E172).
Druge sestavine zdravila so laktoza (glejte poglavje 2 „Zdravilo Anagrelid Mylan vsebuje laktozo“), premreženi natrijev karmelozat, povidon, mikrokristalna celuloza, magnezijev stearat, želatina, titanov dioksid (E171) in črni železov oksid (E172).
Anagrelide is a medicine which interferes with the development of platelets.
Anagrelid je zdravilo, ki ovira razvoj krvnih ploščic.
A capsule size 4 (approximately 14.3 x 5.3 mm) with a grey body and cap.
Kapsula velikosti št. 4 (približno 14,3 x 5,3 mm) s sivim telesom in pokrovčkom.
Effects of other active substances on anagrelide
Učinki drugih učinkovin na anagrelid
INFORMATION IN BRAILLE Carton only: anagrelide mylan 0.5 mg
PODATKI V BRAILLOVI PISAVI Samo na škatli: anagrelid mylan 0,5 mg
• Medicines that can alter your heart rhythm e.g. sotalol, amiodarone;
• zdravila, ki lahko vplivajo na srčni ritem, npr. sotalol, amiodaron;
The contents of the capsules should not be crushed or diluted in a liquid.
Ne sme jih zdrobiti ali raztopiti njihove vsebine v tekočini.
High-density polyethylene (HDPE) bottle of 30 ml or 75 ml with a tamper evident, child-resistant polypropylene (PP) closure with a desiccant.
Plastenka iz polietilena visoke gostote (HDPE) s prostornino 30 ml ali 75 ml s polipropilensko (PP) za otroke varno zaporko, ki omogoča evidentiranje odprtja in s sušilnim sredstvom.
• If you were born with or have family history of prolonged QT interval (seen on ECG, electrical recording of the heart), or you are taking other medicines that result in abnormal ECG changes or if you have low levels of electrolytes e.g. potassium, magnesium or calcium (see section
• če ste se rodili s podaljšanim intervalom QT oziroma imate podaljšan interval QT v družinski anamnezi (vidno na EKG posnetku, električnem posnetku srca) ali pa jemljete druga zdravila,
In male rats, there was no effect on fertility or reproductive performance with anagrelide.
Pri samcih podgan niso opazili učinkov anagrelida na plodnost ali sposobnost razmnoževanja.
Depression Amnesia Confusion Insomnia Paraesthesia Hypoaesthesia Nervousness Dry mouth
Bolezni živčevja glavobol omotica depresija izguba spomina zmedenost nespečnost parestezija hipestezija nervoza suha usta migrenski glavobol disartrija dremavica nenormalna koordinacija
In a pre- and post-natal development study in female rats, anagrelide at oral doses of ≥ 10 mg/kg produced a non-adverse increase in gestational duration.
Anagrelid je v študiji prenatalnega in postnatalnega razvoja pri samicah podgan pri peroralnih odmerkih ≥10 mg/kg povzročil neškodljivo podaljšanje trajanja brejosti.
Therefore, the potential risks of the concomitant use of anagrelide with acetylsalicylic acid should be assessed, particularly in patients with a high risk profile for haemorrhage before treatment is initiated.
Zato je treba pred začetkom zdravljenja ugotoviti morebitna tveganja ob hkratni uporabi anagrelida z acetilsalicilno kislino, še posebej pri bolnikih z velikim tveganjem za krvavitve.
• Medicines used to treat heart disorders, for example, milrinone, enoximone, amrinone,
• zdravila, ki se uporabljajo za zdravljenje motenj srca, npr. milrinon, enoksimon, amrinon, olprinon in cilostazol;
Following repeated oral administration of anagrelide in dogs, subendocardial haemorrhage and focal myocardial necrosis was observed at 1 mg/kg/day or higher in males and females with males being more sensitive.
Pri ponavljajočem peroralnem dajanju anagrelida so pri psih opazili pri odmerku 1 mg/kg/dan ali več subendokardialne krvavitve in fokalno miokardialno nekrozo tako pri samcih kot pri samicah, pri čemer so bili samci občutljivejši.
• If you have moderate or severe kidney problems.
• če imate zmerne ali hude težave z delovanjem ledvic.
• a history of thrombo-haemorrhagic events.
• trombohemoragični dogodki v anamnezi.
Show them the pack of Anagrelide Mylan.
Pokažite mu ovojnino zdravila Anagrelid Mylan.